Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference Read more about Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer Read more about Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference Read more about Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy Read more about Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy
Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015 Read more about Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference Read more about Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference
Aimmune Therapeutics Announces COO Transition Read more about Aimmune Therapeutics Announces COO Transition
Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference Read more about Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Aimmune Therapeutics Reports Second Quarter 2015 Financial Results Read more about Aimmune Therapeutics Reports Second Quarter 2015 Financial Results
